All Whitepapers

Compelling messaging is at the core of every effective pharmaceutical marketing strategy. Whether it is the launch of a new drug or a message refresh project, crisp copy that builds an emotional connection with your target market can help keep communication impactful, without making it highly complex or over-simplistic. Many pharmaceutical companies produce large amounts of unremarkable copy which doesn’t convert. To help you cut through the noise of communication of rival pharma companies, Newristics has created the Ultimate Pharma Messaging Guide with 20 guiding principles that have been scientifically proven to turbocharge pharma communications.

In this application note you will learn the importance of reproducible gene expression quantitation to evaluate host immune response for optimizing safety of gene therapies.

When a company reaches late-stages of clinical trials testing new drugs, systems need to be created to manage the manufacturing, sales, costs, internal controls, and more. A successful transition into commercializing a new drug depends on putting in place the right infrastructure and systems.

Readily available real-world data and advanced solutions are being used to stitch together the full patient journey, and these longitudinal insights are being used to identify and characterize trial populations and inform clinical trial design and execution strategies.

IT Leaders in Life Sciences discuss the consolidation of the learning tech environment to help shift the training effectiveness conversation from anecdotal evidence to data-driven understanding.

In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. While these third-party relationships can be full of risk and regulatory challenges, the right tech can help you navigate the complexities of compliance.

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, new systems were quickly — and possibly haphazardly — put in place to handle snowballing transparency reporting requirements. Now the cracks are beginning to show, and PLS companies are realizing the true cost of transparency reporting.

Digital health platforms, modern delivery models, and edge technologies can transform the way life sciences companies create a virtuous circle of value generation, equipping patients with capabilities that improve health outcomes while providing businesses with valuable data and insights to drive new research, improve stakeholders’ experiences, and accelerate growth. Solutions designed to serve clinical trial participants outside of a clinical setting should be considered as companion services for commercial therapies to drive greater adherence as well as real-world evidence.

Learn about the evolving cyber-threat landscape affecting the pharmaceutical industry and the recommended approach to addressing those threats.

There are three phases of digital transformation needed to reimagine business models, achieve better performance, and create long-term sustainable advantage. It starts with changing our labs—the technologies, processes, ways of working, and data solutions.

According to a survey conducted by Florence Healthcare, 47% of research sites had adopted eConsent by December 2020, just 8 months after the WHO declared an official pandemic. By July 2021, 75% of research sites had either used it or were looking into it. In conclusion - a decentralized consent process is here to stay. Learn why Medable's Total eConsent offering is the industry-leading remote consent technology, and how it can reduce your enrolment timelines by 50%.

In this paper, learn about a variety of genetic analysis methods and how they’re valuable in ensuring that ex vivo human cells used for cell‑based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Download the white paper and read more about the importance of quality control (QC) for isolated human cells and tissues.

For biopharmaceutical developers, optimizing R&D investment in new technologies is an essential way to gain and sustain a competitive edge. Clinical trials present a tremendous opportunity to leverage advanced genetics technologies and practices to improve efficiency and reduce costs.

To get a better understanding of how technology can power superior customer experiences, Salesforce commissioned research to explore what being customer-centric means for life sciences organizations and technology’s role in building stronger connections among people, data, and processes that ultimately lead to better health outcomes.

A leading Swiss pharmaceutical company leveraged Salesforce Health Cloud to drive accelerated and deeper patient engagement by creating an omni-channel, multistakeholder health ecosystem.

The biopharma industry launched COVID vaccines and treatments in record time. How did this impact consumer trust? We asked, and compared survey results with 2017 data.

What if you could predict potential safety issues before clinical development begins? Innovative new signal detection and management approaches have been developed to help clinical trial sponsors, manufacturers, and CROs combat safety-related challenges and provide insight to be used to predict potential safety issues even before clinical development begins. Applying those learnings to their choice of initial research candidates can ultimately mean safer medicines for patients.

With the increasing volumes of adverse event reports and stagnant budgets, the time is now for a revolutionary change in drug and device safety case management. A robust management process is necessary for identifying and evaluating adverse events (AE) and reporting them properly to regulators.